The effect of COQ10 on diabetic type2 patients’ Nephropathies

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N120

Enrollment

Registered

2019-05-18

Start date

2019-06-10

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: The intervention group will received the 100 mg of co-enzyme Q10 capsule daily for 6 months. Intervention 2: The control group will not receive medicine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with proven proteinuria with a rate of greater than 150 mg in 24-hour urine

Exclusion criteria

Exclusion criteria: Presence of underlying diseases, kidney disease and metabolic syndrome Proteinuria because of reasons other than diabetic nephropathy

Design outcomes

Primary

Measure	Time frame
Nephropathy. Timepoint: At the beginning of the study, 3 and 6 months after the study. Method of measurement: Through blood tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNooshin Parvin

Kermanshah University of Medical Sciences

nooshin.parvin@gmail.com+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026